Summary of Significant Accounting Policies and Select Balance Sheet Information (Tables)

12 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Amortized Cost, Unrealized Holding Gains (Losses) and Fair Value of Available for Sale Securities

The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities as of September 30, 2019 and 2018 were as follows (in thousands):

	September 30, 2019
(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
Commercial paper and corporate bonds	$	24,918	$	13	$	—	$	24,931
Total	$	24,918	$	13	$	—	$	24,931

	September 30, 2018
(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial paper and corporate bonds	$	41,403	$	—	$	(51	)	$	41,352
Total	$	41,403	$	—	$	(51	)	$	41,352

Components of Inventories

Inventories consisted of the following components as of September 30 (in thousands):

	2019		2018
Raw materials	$	2,034	$	1,890
Work in-process		892		780
Finished products		1,575		1,346
Total	$	4,501	$	4,016

Schedule of Property, Plant and Equipment

Property and equipment consisted of the following components as of September 30 (in thousands):

	Useful Life	2019			2018
	(In years)
Land	N/A	$	4,415		$	4,420
Laboratory fixtures and equipment	3 to 10		25,467			22,024
Buildings and improvements	3 to 20		24,513			21,717
Leasehold improvements	10		4,836			4,836
Office furniture and equipment	3 to 10		6,476			5,824
Construction-in-progress			2,030			4,834
Less accumulated depreciation			(37,989	)		(33,512	)
Property and equipment, net		$	29,748		$	30,143

Summary of Other Assets

Other assets consist principally of the following as of September 30 (in thousands):

	2019		2018
ViaCyte, Inc.	$	479	$	479
Other noncurrent assets		1,645		967
Other assets, net	$	2,124	$	1,446

Schedule of Intangible Assets

Intangible assets consisted of the following as of September 30 (in thousands):

	2019
	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	17,374	$	(10,661	)	$	6,713
Developed technology		11.5		9,490		(3,196	)		6,294
Non-compete		5.0		230		(196	)		34
Patents and other		16.5		2,321		(1,716	)		605
Subtotal				29,415		(15,769	)		13,646
Unamortized intangible assets:
Trademarks and trade names				580		—			580
Total			$	29,995	$	(15,769	)	$	14,226

	2018
	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	18,086	$	(9,377	)	$	8,709
Developed technology		11.5		9,656		(2,361	)		7,295
Non-compete		5.0		230		(150	)		80
Patents and other		16.5		2,321		(1,569	)		752
Subtotal				30,293		(13,457	)		16,836
Unamortized intangible assets:
In-process research and development				267		—			267
Trademarks and trade names				580		—			580
Total			$	31,140	$	(13,457	)	$	17,683

Estimated Amortization Expense

Based on the intangible assets in service as of September 30, 2019, estimated amortization expense for each of the next five fiscal years is as follows (in thousands):

2020	$	2,414
2021		2,275
2022		2,235
2023		1,629
2024		1,584

Schedule Of Carrying Amount Of Goodwill By Segment

The change in the carrying amount of goodwill by segment for the years ended September 30, 2019 and 2018 was as follows (in thousands):

(Dollars in thousands)	In Vitro Diagnostics		Medical Device			Total
Balance as of September 30, 2017	$	8,010	$	19,272		$	27,282
Foreign currency translation adjustment		—		(250	)		(250	)
Balance as of September 30, 2018		8,010		19,022			27,032
Foreign currency translation adjustment		—		(861	)		(861	)
Balance as of September 30, 2019	$	8,010	$	18,161		$	26,171

Schedule of Other Accrued Liabilities

Other accrued liabilities consisted of the following as of September 30 (in thousands):

	2019		2018
Accrued professional fees	$	434	$	311
Accrued clinical study expense		2,163		2,839
Accrued purchases		679		533
Acquisition of in process research and development		989		—
Deferred rent		130		121
Other		395		262
Customer claim		—		1,000
Construction in progress		—		1,199
Total	$	4,790	$	6,265

Denominator for Computation of Basic and Diluted Income Per Share

The following table sets forth the denominator for the computation of basic and diluted income per share for each of the years ended September 30 (in thousands):

	2019		2018			2017
Net income (loss) available to common shareholders	$	7,592	$	(4,457	)	$	3,926
Basic weighted average shares outstanding		13,389		13,157			13,153
Dilutive effect of outstanding stock options, non-vested    restricted stock, restricted stock units and performance    shares		390		—			236
Diluted weighted average shares outstanding		13,779		13,157			13,389

Impact of Adoption of ASC Topic 606 on Consolidated Balance Sheet

The impact of the adoption of ASC Topic 606 on the opening consolidated balance sheet as of October 1, 2018, as compared with the consolidated balance sheet previously reported as of September 30, 2018, was as follows:

(Dollars in thousands)	September 30, 2018, As Reported		Adjustments for Adoption of Topic 606			October 1, 2018 Opening Balance
Assets
Contract assets - royalties and license fees	$	—	$	6,904		$	6,904
Deferred income taxes		6,304		(1,215	)		5,089
Income tax receivable		1,152		(390	)		762
Liabilities and Stockholders' Equity
Deferred revenue, current portion		9,646		(18	)		9,628
Deferred revenue, less current portion		11,247		(181	)		11,066
Retained earnings		97,615		5,498			103,113